{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-098371","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.526319+00:00","generated_at":"2026-05-31T05:40:44.964411+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Passage Bio appoints Thomas Kassberg as Class I director and Audit Committee member","bullets":["Appointment effective September 10, 2024; Kassberg also joins Audit Committee.","Kassberg currently Chief Business Officer and EVP at Ultragenyx Pharmaceutical.","Received non-incentive stock options with $90,000 grant date fair value, vesting over three years.","Cash compensation per non-executive director policy plus indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-098371","json":"https://secwatch.observer/filing/0001104659-24-098371.json","markdown":"https://secwatch.observer/filing/0001104659-24-098371.md","text":"https://secwatch.observer/filing/0001104659-24-098371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924098371/0001104659-24-098371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924098371/tm2423395d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:40:44.964411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cd0a4cbea","claim":"Thomas Kassberg was appointed as Class I director at Passage BIO, Inc..","evidence_excerpt":"On September 9, 2024, the board of directors (the “ Board ”) of Passage Bio, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Thomas Kassberg as a Class I director and as a member of the Audit Committee of the Board, effective as of September 10, 2024 (the “ Appointment Date ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924098371/0001104659-24-098371-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}